| Literature DB >> 18941112 |
Anne Saumet1, Guillaume Vetter, Manuella Bouttier, Elodie Portales-Casamar, Wyeth W Wasserman, Thomas Maurin, Bernard Mari, Pascal Barbry, Laurent Vallar, Evelyne Friederich, Khalil Arar, Bruno Cassinat, Christine Chomienne, Charles-Henri Lecellier.
Abstract
Micro(mi)RNAs are small noncoding RNAs that orchestrate many key aspects of cell physiology and their deregulation is often linked to distinct diseases including cancer. Here, we studied the contribution of miRNAs in a well-characterized human myeloid leukemia, acute promyelocytic leukemia (APL), targeted by retinoic acid and trioxide arsenic therapy. We identified several miRNAs transcriptionally repressed by the APL-associated PML-RAR oncogene which are released after treatment with all-trans retinoic acid. These coregulated miRNAs were found to control, in a coordinated manner, crucial pathways linked to leukemogenesis, such as HOX proteins and cell adhesion molecules whose expressions are thereby repressed by the chemotherapy. Thus, APL appears linked to transcriptional perturbation of miRNA genes, and clinical protocols able to successfully eradicate cancer cells may do so by restoring miRNA expression. The identification of abnormal miRNA biogenesis in cancer may therefore provide novel biomarkers and therapeutic targets in myeloid leukemias.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18941112 DOI: 10.1182/blood-2008-05-158139
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113